AAV-GAD gene therapy trial reaches full enrollment by year-end
MeiraGTx's Phase 1/2 clinical trial testing AAV-GAD, an investigational gene therapy for Parkinson's disease, is expected to be fully enrolled by the end of the year. The trial aims to evaluate the safety and efficacy of AAV-GAD in easing motor symptoms in Parkinson's patients. The gene therapy delivers a working copy of the GAD gene to neurons in the subthalamic nucleus, a brain region involved in movement control. The therapy is administered through an infusion directly into the brain. MeiraGTx is also planning a potential pivotal clinical trial for 2024.